NASDAQ:CAI
Caris Life Sciences, Inc.
Caris Life Sciences, Inc.'s revenue grew 97.0% in fiscal 2025 to $812.0M while operating margin rose to 5.6%, its highest in 3 years. Free cash flow was $66.9M, 8.2% of revenue, and the diluted share count rose 371.0%.Summary generated from Caris Life Sciences, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$812.0M
Revenue growth+97.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin5.6%
Net margin−8.4%
ROICn/a
Return on equityn/a
Debt / equity0.66
Free cash flow$66.9M
FCF margin8.2%
Share count change+371.0%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 306 | 412 | 812 |
| Operating income | −320 | −257 | 45 |
| Net income | −341 | −282 | −68 |
| Free cash flow | −298 | −254 | 67 |
Recent filings
- 4Insider transaction report
Sep 23, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KResults of a shareholder vote
Jun 5, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026 - 8-KResults of operations and financial condition
May 7, 2026